Analysts await Solazyme, Inc. (NASDAQ:SZYM) to report earnings on Mar, 14 for the fiscal quarter ending Dec 2015.

They expect $-0.41 EPS, up 31.71% or $0.13 from last year’s $-0.54 per share.

At the moment 4 analysts are watching Solazyme, Inc. (NASDAQ:SZYM), 1 rate it “Buy”, 0 “Outperform”, 3 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 3 analysts have a mean sales target of 13.39 million. For the quarter ending Jun-16, 3 analysts have a mean sales target of 15.04 million whilst for the year ending Dec-16, 4 analysts have a mean target of 77.69 million.

In terms of earnings per share, 2 analysts have a -0.27 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -0.25 EPS mean target and for the quarter ending Jun-16 there are 3 estimates of -1.10 EPS.

Total shares held by institutions as of the most recent company filings are 33,163,755 with a reported 1,054,900 bought and 1,737,745 sold. These holdings make up 41.2% of the company’s outstanding shares.

The stock increased 23.60% or $0.38 during the last trading session, hitting $2.75. Solazyme, Inc. (NASDAQ:SZYM) has fallen 8% over the past 6 months and is downtrending.